All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON - Armetheon Inc. is poised to open the pivotal phase III trial of its oral anticoagulant, tecarfarin, and is raising a private round to fund the 3,000-patient study, which has FDA special protocol assessment (SPA) status.